The FDA has approved galcanezumab (Emgality), a monoclonal antibody directed against calcitonin gene-related peptide (CGRP), for the treatment of episodic cluster headache in adults. The effectiveness of galcanezumab has been demonstrated in a number of phase 3 studies including EVOLVE-1 and EVOLVE-2 for episodic migraine and REGAIN for chronic migraine. “Emgality provides patients with the ...
Already a member?
Enter your email to keep reading.